William Blair & Company
CLDX icon

William Blair & Company’s Celldex Therapeutics CLDX Stock Holding History

William Blair & Company’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-633
Closed -$240K – 1423
2015
Q2 		$240K Hold
633
– – ﹤0.01% 2005
2015
Q1 		$265K Buy
+633
New +$226K ﹤0.01% 1924
2014
Q1 		– Sell
-633
Closed -$230K – 2036
2013
Q4 		$230K Hold
633
– – ﹤0.01% 1824
2013
Q3 		$337K Buy
+633
New +$217K ﹤0.01% 1688

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

William Blair & Company's CLDX Position: Q3 2015 in Review

William Blair & Company sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 633 shares — an estimated $240K sold.

William Blair & Company first reported a position in CLDX in Q3 2013 and held it in 4 quarters. The position peaked at $337K in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • William Blair & Company reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • William Blair & Company sold 633 Celldex Therapeutics shares in Q3 2015, an estimated $240K.
  • William Blair & Company first reported a position in Celldex Therapeutics in Q3 2013 and held it in 4 quarters.
  • William Blair & Company's Celldex Therapeutics position peaked at $337K in Q3 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on William Blair & Company's 13F filing for Q3 2015, filed 12 Nov 2015.